- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 403491, 12 pages
In Vitro Cytotoxicity and In Vivo Acute and Chronic Toxicity of Xanthii Fructus and Its Processed Product
Yunnan University of Traditional Chinese Medicine, Kunming, Yunnan 650500, China
Received 27 July 2013; Revised 11 October 2013; Accepted 11 October 2013
Academic Editor: Swaran J. S. Flora
Copyright © 2013 Jie Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Xanthii Fructus (XF), the fruit of Xanthium sibiricum Patr., was used in the treatment of rhinitis and related nasal disease. Adverse effects of Xanthii Fructus are frequently reported these years. In the paper, in vitro renal cytotoxicity and in vivo acute and chronic toxicity researches of Xanthii Fructus (XF) and its processed product (processed Xanthii Fructus (PXF)) were carried out. Water extraction of XF displayed no cell membrane damage effects even in the highest concentration (100 μg/mL); however, it might affect the function of renal cell mitochondria. Acute toxicities were observed only in high and middle dosage groups. Fortunately, the single dose administration of XF or PXF was safe even at the highest daily dosage. Twelve-week chronic toxicity assays were performed in SD rats with low, middle, and high dosage. Notable changes in body weight and blood cell and BUN and Scr changes sporadically occurred in middle and high groups after the 9th week. Serum HA and HPCIII values were sustained increasing from the 4th week to the 8th week in Group V male rats, which indicated that the renal fibrosis risks still existed although no fibrosis was found in the pathological examination of the liver and kidney.
Concerns about the toxicity of traditional Chinese medicines are increasing with each passing day after the “aristolochic acid nephropathy” case. Aristolochic acids are hypothesized to be causative agents in Balkan endemic nephropathy and a related possibly identical condition known as “Chinese herbs nephropathy” .
Hereafter, adverse effects of traditional Chinese medicine other than aristolochic acid related crude drugs, such as Xanthii Fructus, Polygoni Multiflori, and Leonuri Herba, are frequently reported [2–8]. Among them, Xanthii Fructus attracts our intensive attention due to its wide range of applications in the treatment of rhinitis, snuffle, nasosinusitis, and related nasal disease. Xanthii Fructus is the fruit of Xanthium sibiricum Patr. . Xanthii Fructus is the most frequently used crude drug in compound recipes, which were used in the treatment of rhinitis. Xanthii Fructus is recorded as nontoxic in the ancient herbal “Shen Nong Ben Cao Jing” (Shen Nong’s Classic of Materia Medica, composed in about AD 1082). Nevertheless, its toxicity is recognized gradually as time goes by. It is recorded as slight noxious or middle level noxious in most of the ancient herbals, such as Zheng Lei Ben Cao (composed in about AD 1082) and Pin Hui Jing Yao (composed in about AD 1505).
Unfortunately, although the toxicity of Xanthii Fructus is clearly alerted in the Pharmacopoeia of China (2010 edition) , poisoning even death cases are reported continuously after immoderate usage of Xanthii Fructus as food or medicine. The authors have reviewed the clinic toxicity reports of Xanthii Fructus systematically . Three death cases caused by multiple organ failure were reported  in Turkey (no clear dosage reported). An outbreak characterized by vomiting and rapid progression to unconsciousness and death was reported in northeastern Bangladesh after the consumption of Xanthium strumarium seedlings in large quantities, due to inaccessibility of other foods . Kidney damage was the most frequently reported adverse effect caused by Xanthii Fructus . Hematuria, albuminuria, abnormal renal function, and acute renal failure were the most presented renal damage types [2, 4]. Judging from all the adverse effects reports, we find that most of these severe adverse effects are occurred in the high dosage or even overdose administration cases.
The toxicity of Xanthii Fructus is usually considered to be associated with two diterpenoids glycosides, atractyloside (AL) and carboxyatractyloside (CAL). The biochemistry and toxicology of them are well investigated and elucidated both in in vitro and in vivo [10, 11] methods. The LD50 of AL is 15 mg/kg in dog (iv), 434 mg/kg in mouse (ip), and 143 mg/kg in rat (ip). According to the latest literature , content of CAL decreased dramatically after processing procedure, while AL content increased after processing procedure. CAL was reported to be about 1.16 mg–2.25 mg/g in XF and 0–0.21 mg/g in PXF. On the other hand, AL could not be detected in XF; however, the content of AL increased to about 0.17–2.56 mg/g in PXF. However, the toxicity mechanisms involved are not well investigated.
Despite the prevalent reports of their toxicity, the toxicity research data about XF and PXF still need to be clarified, especially, their toxicity in normal or middle dosage administration case. In this paper, we systemically evaluated the in vitro and in vivo toxicity of Xanthii Fructus, its processed product, and its major chemical constituent.
In vitro renal cytotoxicities were investigated by human kidney HK-2 cell line, an immortalized proximal tubular epithelial cell line from normal adult human male kidney, retaining the phenotype and functional characteristics indicative of well-differentiated proximal tubular epithelial cell . Not only the water extracts of Xanthii Fructus but also its major chemical constituents, atractyloside potassium salt (AL), were involved. Culture of this cell line has previously been employed by several studies to investigate nephrotoxicity of various toxic compounds [13–15].
Acute and chronic toxicities were tested in Kunming mice and SD rats, respectively. Single dosage of XF or PXF was given to Kunming mice in order to investigate their acute toxicity. Twelve-week chronic toxicity assay was also conducted in rats. Systemic toxicity indexes were involved in both acute and chronic toxicity assays in order to elucidate their toxicity comprehensively. Some kidney toxicity indexes and early indicators of renal fibrosis were involved in chronic toxicity assays.
2. Materials and Methods
3-(4,5)-Dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) and trypsin (1 : 250) were acquired from Amresco, USA. Dimethylsulfoxide (DMSO) was purchased from Sigma, USA. Other reagents were all above analytical grade. Lactate dehydrogenase (LDH) assay kits were purchased from Changchun Huili Biotech Co., Ltd., China. BUN and Scr assay kits were purchased from Biosino Bio-technology & Science Inc., China. Enzyme-linked immunosorbent assay kits of HA, LN, and HPC III, three early indicators of renal fibrosis, were obtained from Cusabio Biotech Co. Ltd, Wuhan, China.
2.2. Processing Procedure of Xanthii Fructus
Xanthii Fructus was purchased from Juhuacun Chinese herbal medicine market, Kunming, Yunnan, China, in February, 2009 (shown in Figure 1), and was identified as fruit of Xanthium sibiricum Patar. by the author, Associate Professor Jie Yu. Voucher specimens were deposited in the Herbarium of Pharmacognosy, Yunnan University of Traditional Chinese Medicine.
Processed Xanthii Fructus was stir-fried from Xanthii Fructus with mild fire to yellowish brown (Figure 1). Processing of Xanthii Fructus was carried out by the authors according to the procedures documented in the Pharmacopoeia of China, 2010 edition .
2.3. In Vitro Renal Cytotoxicity Assay
2.3.1. Preparation of Exposure Solution of Atractyloside Potassium Salt for In Vitro Assay
Atractyloside potassium salt (AL), major constituent of XF and PXF, was purchased from Sigma, USA (structure shown in Figure 2), with purity higher than 98%. The exposure solutions of AL in concentration from 2.5 to 320 μM were diluted by RPMI 1640 containing 0.2% fetal bovine serum (FBS).
2.3.2. Preparation of Extraction of Xanthii Fructus for In Vitro Assay
40 g powder of XF was decocted with water (1000 mL, 800 mL, and 600 mL) for 3 times, respectively. The extractions were combined, condensed, and lyophilized. Extraction yield was 23.15%.
XF stock solution was achieved by dissolving them in DMSO at a concentration of 10 mg/mL. Then dissolving in DMSO, it was further diluted with 0.2% FBS-RPMI 1640 to graded concentrations from 10 to 100 μg/mL.
2.3.3. Culture Conditions
The whole research was carried out by HK-2 cells, immortalized proximal tubular epithelial cell line, which were purchased from Cell Bank, Kunming Institute of Zoology, Chinese Academic of Science. Cells were cultured in monolayer culture in DMEM medium (Gibco Invitrogen Corp.), supplemented with 10% fetal bovine serum (HyClone).
Cells were seeded at an appropriate cell density in a humidified incubator (Series II water jacketed CO2 Incubator Model 3111, Thermo Electron Corporation, USA) with 5% carbon dioxide and dioxide, 95% air at 37°C for different assay and left to grow to 80-90% confluence.
2.3.4. MTT Cell Viability Assay
This assay procedure was adopted from the previous report . HK-2 cells were seeded in 96-well plates (Corning Incorporated) at a cell density of 2 × 104 in 200 μL/well and then incubated for 48 h till 80–90% confluence. Then, the cell synchronization was routinely accomplished by incubating cells in G0 medium for 12 h before the test. Subsequently, cells were exposed to fresh G0 medium with various concentrations of test compounds or extractions for 24 h.
At the end of the incubation period, 10 μL/well of 5 mg/mL MTT (Amresco, USA), which was dissolved in PBS (pH 7.4) and sterilized by filtrating through a Millipore filter (0.22 μm), was added in medium for a further 4 h incubation; then the medium was removed and 100 μL DMSO was added to dissolve the resulting intracellular purple formazan product. The 96-well plates were gently swirled for 5 min in room temperature. The absorbance was measured at 570 nm. This was conducted by a microtiter plate reader (DNM-9602G, Beijing Perlong Medical Equipment Co., Ltd.). The wells added with cell and culture medium but without stimulus were considered as normal control, and the wells added culture medium only were considered as blank control. HgCl2 (10 μM), a typical renal toxicant, was used as a positive control. Each concentration of tested compounds or extractions was paralleled for three times and 6 wells were averaged in each plate. The survival rate of cells in each concentration was calculated.
2.3.5. LDH (Lactate Dehydrogenase) Leakage Assay
This assay procedure was adopted from the previous report . HK-2 cells were seeded in 24-well plates (Corning Incorporated) at a cell density of 1 × 104 in 500 μL/well and then incubated till the cells reached 80–90% confluence. Then, the cell synchronization was routinely accomplished by incubating cells in G0 medium for 12 h before the test. Subsequently, cells were exposed to fresh G0 medium with test compounds or extraction for 24 h. At the endpoint of the incubation period, all the culture medium was collected and the intracellular LDH was ingathered after lysing cells with 500 μL 0.1% Triton X-100 (Sigma). The enzyme content in culture medium and cell lysis solution was analyzed by lactate dehydrogenase kit by an UV detector (725, Shanghai Spectrum Instruments Co., Ltd.). The leakage percentage was calculated by the extracellular LDH activity compared with the total LDH activity (extracellular + intracellular LDH). HgCl2 (10 μM) was used as a positive control. Two wells were repeated in each 24-well plate and three plates were paralleled for different concentrations of each compound or extraction.
2.4. In Vivo Acute and Chronic Toxicity Assays
Acute toxicity research was carried out on Kunming mice of both sexes. 70 Kunming mice were provided by the Experimental Animal Center of Yunnan University of Traditional Chinese Medicine. They were aged 5 weeks and weighed 18~22 g. Mice of the same sex were housed ten in a stainless steel cage containing sterile paddy husk as bedding in ventilated animal rooms.
Chronic toxicity research was carried out on SD rats of both sexes, which were also provided by the Experimental Animal Center of Yunnan University of Traditional Chinese Medicine. They were aged 6 weeks and weighed 200 ± 20 g. Rats of the same sex were housed four in a stainless steel rat cage containing sterile paddy husk as bedding in ventilated animal rooms.
All mice and rats were acclimated in the controlled environment (temperature 22 ± 1°C, 60 ± 10% humidity, and a 12 h/12 h light/dark cycle) with free access to water and a commercial laboratory complete food. All animal experiments were performed in compliance with the animal experimental ethics committee of Yunnan University of Traditional Chinese Medicine. All reasonable efforts were made to minimize the animals’ suffering.
2.4.2. Preparation of Extraction of Xanthii Fructus for In Vivo Toxicity Assay
500 g Xanthii Fructus was immersed in water for an hour. Then, they were decocted with water (2500 mL, 1500 mL, and 1500 mL) for 3 times, 30 mins per time, respectively. The extraction was combined and condensed to 10 g/mL (the maximum concentration that can flow through the gavage needle for mice). The same procedure was adopted in the preparation of processed Xanthii Fructus extraction.
The recommended dosages of XF and PXF were both 3–10 g/per day according to the Pharmacopoeia of the People’s Republic of China, 2010 edition . The low, middle, and high dosages of XF and PXF in acute toxicity assay for mice were 16.68 g/mL (10 times the highest human dosage), 166.8 g/mL (100 times the highest human dosage), and 400 g/mL (240 times the highest human dosage).
Much lower dosages were adopted in the chronic toxicity assay in order to imitate the human clinic medication practice of XF and PXF. In the chronic toxicity assay, the low, middle, and high dosages of XF and PXF were 0.585 g/mL (the same as the human median dosage), 1.755 g/mL (3 times the human dosage median dosage), and 5.265 g/mL (9 times the human dosage median dosage).
2.4.3. Acute Toxicity Testing
All mice of both sexes were randomly divided into 7 groups of ten each (Table 1). The male and female rats were all five in each group. All mice fasted for 12 h before the administration of each agent. Group A received physiological saline only and served as vehicle. Group B to G received water of XF or PXF in low, middle, and high dosage, respectively (Table 1).
Clinical symptoms of mice after respective treatments were monitored closely for 4 hr after gavage. Seven-day observation was carried out on all the surviving mice. Mortalities, clinical signs, time of onset, duration, and reversibility of toxicity in each group were recorded. Gross necropsies were performed on all animals, including those sacrificed moribund, found dead, or terminated at 7 days. Routine analysis of blood cells in Groups A, B, C, E, and F was carried out after the sacrifice in the end of the research. For light microscopic observations, samples from liver, kidney, lung, and heart of each group were fixed in formalin fixative and processed routinely for embedding in paraffin. Both male and female mice samples were used in the histopathological examination. Tissue sections in 5 μm thickness were stained with hematoxylin and eosin (H&E) and examined under a light microscope.
2.4.4. Chronic Toxicity Assays
A 12-week chronic toxicity assay was executed to investigate the long term toxicity after normal dosage administration of XF and PXF every day. 56 rats of both sexes were randomly divided into 7 groups of eight each (Table 2). The male and female rats were all four in each group. Group I received physiological saline only and served as vehicle. Group II to IV received water extraction of XF, while Group V to VII got PXF water extraction in various dosages. All rats fasted for 2 h before administration of each agent every day.
Body weights were recorded every three days till the end. Samples of blood 1.5–2 mL in volume were collected from the retro-orbital venous plexus once every week throughout the study. Blood samples were collected under ether anesthetic condition, two hours after the administration of therapeutic agents in the morning. Routine analysis of blood cells was performed by hematology analyzer (URIT-2900, Guiling, China). Levels of BUN and Scr were determined by enzymatic colorimetric method using commercial assay kits (Biosino Bio-technology & Science Inc.) by AB-1020 automatic biochemical analyzer (Sunostik Medical Technology Co., Ltd.). As early indicators of renal fibrosis, serum HA, LN, and HPCIII content values were also tested in our research. They were analyzed using enzyme-linked immunosorbent assay kits from Cusabio Biotech Co., Ltd. (Wuhan, China). HA, LN, and HPCIII were tested only on weeks 4, 8, and 12. All bioassays were carried out in duplicate.
For light microscopic observations, samples from liver and kidney of each group were fixed in formalin fixative and processed routinely for embedding in paraffin. Both male and female samples were used in the histopathological examination. Tissue sections in 5 μm thickness were stained with hematoxylin and eosin (H&E) and examined under a light microscope.
2.5. Statistical Analysis
All data in this research were expressed in the form of mean ± SD. One-way analysis of variance (ANOVA) was performed when multiple group comparisons were carried out. Results were classified into three significance levels using the value of 0.05, 0.01, and 0.001.
3.1. In Vitro Renal Cytotoxicity of Atractyloside Potassium Salt
In order to avoid overestimation or underestimation of the toxicity of a substance, incubations with various concentrations are required to distinguish between effects on specific organelles or general cytotoxicity. More than one assay should be used to determine cell viability in in vitro studies, as this would increase the reliability of the results obtained [8, 16]. In this research, both MTT and LDH assays, reflected the function of mitochondria and cell membrane, were adopted.
As listed in Table 3, AL showed no inhibition on the cell proliferation of HK-2 cells in MTT survival rate assay. The cell survival rate was not affected by the exposure of AL, and it almost remained at 100% even at the highest concentration of 320 μM. Meantime, the LDH leakage rate was not affected by the exposure of AL, and it almost remained at 10% (similar to the control group) even at the highest concentration of 320 μM.
Judging from these data, AL not only showed no inhibition on the cell proferliation of HK-2 cells but also exhibited no damage on the cell membrane function.
3.2. In Vitro Renal Cytotoxicity of Xanthii Fructus
Results of renal cytotoxicity assay of water extraction of XF were shown in Figure 3. MTT survival rates ranged from 70% to 90% in the 10 to 80 μg/mL XF water extraction. However, the survival rate decreased to 63.0 ± 2.7% in the 100 μg/mL XF water extraction. Water extraction of Xanthii Fructus showed moderate inhibition effects on proliferation of HK-2 cells in high dosage (Figure 3(a)). On the other hand, we find that the HK-2 cell membrane remains undamaged even in the highest 100 μg/mL XF water extraction exposure (Figure 3(b)).
3.3. In Vivo Acute Toxicity of XF and PXF
In the in vivo acute toxicity assay, close observations of mice clinic signs were made before dosing and up to four hours immediately after dosing. All animals were observed daily for convulsions, excitement, posture, piloerection, breathing difficulty, sedation, anorexia, diarrhea, hemorrhage, and death during the 7-day assay period.
Deaths were observed only in high dosage XF and PXF group. Mortality rate in XF group (80%) was significantly higher than that in PXF group (40%) in both sexes. No death was found in middle or low dosage group no death was found in middle or low dosage group. Regular acute toxicity symptoms and signs, such as salivation, slow action, and convulsions, were observed in middle or high XF and PXF groups (Table 4).
Postmortem examination did not reveal any gross abnormality of the brain and the organs of the chest and abdominal cavities in all treated groups. Liver and kidney pathological examination of dead mice showed the congestion and focal necrosis in the liver and renal tubules (Figure 4). Pathological damage in the heart and lung in high dosage XF and PXF groups was reported for the first time.
Blood samples of high dosage XF and PXF groups were hard to collect due to the close death time. Therefore, blood cell analysis was conducted only in the middle and low dosage XF and PXF groups (Table 5). Most of the blood cell indexes, such as white blood cells (WBC), red blood cells (RBC), haemoglobin (HGB), and platelet (PLT), in low dosage XF and PXF groups remained at normal level compared with control group. However, the PLT content decreased significantly in high dosage PXF group. This indicated that thrombocytopenia might be an obvious adverse effect of XF.
Judging from the mortality rate, toxicity symptoms and signs, tissue morphology, and blood cell analysis results, neither XF nor PXF showed acute toxicity in the low dosage group. That indicated that the single dose administration of XF or PXF was safe even at 10 times of the allowed human highest daily dosage. However, higher dosages of XF and PXF both displayed obvious acute toxicity. 40% of the mice in high dosage PXF group and 80% of the mice in high dosage XF group were dead with severe kidney, liver, heart and lung morphology changes within the 7-day observation period. Fortunately, PXF showed more moderate acute toxicity effects than XF in the same dosage level.
3.4. In Vivo Chronic Toxicity of XF and PXF
12-week administrations of water extraction of XF and PXF in low, middle, and high dosage were conducted in order to investigate their chronic toxicity. Taking into account the clinic dosage, the low, middle, and high dosages of this chronic toxicity research were set as 0.585, 1.755 and 5.265 g/kg body weight.
Nineteen rats were dead during the research procedure (Table 6). Nine of them were dead immediately after our experimental operations, such as excessive anesthesia and blood sample collection procedure. These deaths might be most probably related to the experimental operations. The other 10 rats were dead probably due to the administrations of XF and PXF. Most of the 10 rats were dead during the 10th to 12th weeks. Four of them were in XF treatment groups and 6 of them were in PXF groups. Four of the 10 rats were female, while 6 of the 10 rats were male. A total of 1, 2, and 1 rats were dead in the low, middle, and high dosage groups, respectively. A total of 4, 1 and 1 rats were dead in the low, middle, and high dosage groups, respectively. No obvious dose-toxicity relationship was observed.
Postmortem examination did not reveal any gross abnormality of the brain and the organs of the chest and abdominal cavities. Histopathological examinations of kidney, liver, heart and lung samples were all carried out. However, no obvious pathological changes were found in the heart and lung samples. Liver and kidney pathological examination of dead mice showed congestion and focal necrosis in the liver and renal tubules (Table 7 and Figure 5) without a dose-dependent relationship.
No significant body weight changes were observed in both male and female rats in the first 8 weeks of this research (data not shown). Obvious body weight changes were found after the end of the 8th week (Figure 6). Body weights (BWs) of female rats in all treated groups were reduced, although only female rats in Group III (9th, 10th, and 11th weeks) and Group VII (11th week) were significantly lighter than those in Group I (Control I) in statistical level. Body weight losses were more conspicuous in male rats groups. The mean body weight of Group III was about 80% of the control group.
Blood cell analysis was conducted in all treatment groups from the 3rd to the 12th weeks (data not shown); however, no significant alterations were observed in all groups compared to the control group. This indicated that the 3-month administration would not affect the composition and content of basic blood cell, such as WBC, RBC, HGB, and PLT.
Scr and BUN were analyzed from the 3rd to the 12th weeks. Similar change trends were observed in Scr and BUN results (in Figures 7 and 8 and Supplementary Tables 1–4 in Supplementary Material available online at http://dx.doi.org/10.1155/2013/403491). Increasing BUN compared to Group I (control group) was observed only in female rats in Group IV (high dosage XF) and Group VII (high dosage PXF) from the 10th to the 12th weeks (Figure 7). Sporadic and transient Scr increases appeared only in the 8th (Group VI) and the 11th (Groups II and VII) weeks for female rats and the 8th (Groups III and VI) weeks for male rats (Figure 8). BUN values were even decreased in male rats in Group VII.
In conclusion, low and middle dosage of XF and PXF would not induce serum BUN alteration even in a three-month chronic research. High dosage PXF even decreased the BUN compared to high dosage XF in male rats in the 9th, 10th, and 11th weeks. Scr alterations were not sustained but irreversible in both female and male rats in all dosage XF and PXF groups.
As early indicators of renal fibrosis, serum HA, LN, and HPCIII content values were also tested in our research (Tables 8, 9, and 10). Some transient increasing of them were found. Although no HA, LN, and HPCIII increase was found at the end of the research, we still noticed that serum HA and HPCIII values were sustained increasing from the 4th week to the 8th week in Group V male rats. Whether this increase is related to the death of these rats still need to be investigated. That indicated that the renal fibrosis risks still existed although no fibrosis was found in the pathological examination of liver and kidney.
Adverse effects of Xanthii Fructus were frequently reported in recent years, although the toxicity of Xanthii Fructus is clearly alerted in the Pharmacopoeia of China (2010 edition). Moreover, its basic toxicity data and related mechanism were not well investigated. In this manuscript, we systemically evaluated the in vitro and in vivo toxicity of Xanthii Fructus, its processed product, and its major chemical constituent.
In the HK-2 renal cells, water extraction of XF displayed no cell membrane damage effects even in the highest 100 μg/mL concentration; however, it might affect the function of renal cell mitochondria.
Atractyloside was frequently reported to be a toxic substance of Xanthii Fructus. The toxic mechanisms of atractyloside were also well explained. Atractyloside competitively inhibits the adenine nucleoside carrier in isolated mitochondria and thus blocks oxidative phosphorylation . Atractyloside inhibits gluconeogenesis and fatty acid oxidation but accelerates anaerobic glycolysis and glycogenolysis. The metabolic alterations in humans and animals include an acute hyperglycaemic phase, due to rapid depletion of skeletal muscle and hepatic glycogen, inhibition of glycogen synthesis, and a subsequent marked hypoglycaemic phase. The rapidly declining plasma glucose resulted in insufficient glucose delivery to the brain to sustain normal functions. As the severe hypoglycaemia persisted, depression of respiration, hypoxaemia, tissue hypoxia (diminished oxygen consumption), acidosis, convulsion, coma, and, in some cases, death followed. However, in this experiment, atractyloside did not show such obviously toxic effects as other published researches. We consulted this to the differences between in vitro and in vivo research results. Limited metabolic enzyme and limited exposure time might restrict the exposure of atractyloside toxicity. Moreover, toxic effects induced by atractyloside might be mediated by its in vivo metabolite, which could not happen in our in vitro experiment system.
In vivo toxicity assays provided more information and basic data for the clinical usage of Xanthii Fructus. Both XF and PXF displayed severe acute toxicity in 240 times of human highest dosage; however, this dosage was too extreme in the clinical usage. Fortunately, the single dose administration of XF and PXF was safe even at 10 times of allowed human highest daily dosage. No obvious behavioral changes, blood cell analysis results changes, and general organ lesions were observed in this dosage.
Chronic toxicity assays focused on the more common dosage with high probability of occurrence in clinical practice. In order to evaluate their toxicity to kidney, BUN and Scr were tested as the function index of kidney. The BUN test, along with the creatinine test, is primarily used to evaluate kidney function in a wide range of circumstances to help diagnose kidney disease and to monitor people with acute or chronic kidney dysfunction or failure. Increased BUN levels suggest impaired kidney function. This may be due to acute or chronic kidney disease, damage, or failure. It may also be due to a condition that results in decreased blood flow to the kidneys, such as congestive heart failure, shock, stress, recent heart attack, or severe burns, due to conditions that cause obstruction of urine flow, or due to dehydration. Moreover, HA, LN, and PCIII, the major ingredients of extracellular matrix (ECM), were also evaluated. Synthesis and accumulation of large quantities ECM were foundations of kidney fibrosis.
Twelve-week administrations of low, middle and high dosage of XF and PXF were performed in SD rats. Notable changes in body weight and blood cell and BUN and Scr changes occurred sporadically in middle and high dosage groups after the 9th week. Although some liver and kidney pathological damage was found in the high dosage groups, no early stage changes of renal fibrosis were found.
All the above results indicated that the single use of even 10 times the permitted highest dosage of XF and PXF is safe. However, long-term usage of overdose XF and PXF was not entirely safe. Adverse effects or even death casesoccurred after continuous administration of 3 times or 9 times the permitted dosage of XF and PXF for 2 months.
|AL:||Atractyloside potassium salt|
|BUN:||Blood urea nitrogen|
|FBS:||Fetal bovine serum|
|HPCIII:||Human procollagen type III|
|LD50:||Median lethal dose|
|NRU:||Neutral red uptake assay|
|PXF:||Processed Xanthii Fructus|
|RBC:||Red blood cells|
|RPMI 1640:||Roswell Park Memorial Institute medium 1640|
|WBC:||White blood cells|
Conflict of Interests
The authors declare that there is no conflict of interests. They declare that they have no financial and personal relationships with other people or organizations that can inappropriately influence their work; there is no professional or other personal interest of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in this paper.
Jie Yu and Mei Zhen Song contribute equally to the work.
- M. E. De Broe, “Chinese herbs nephropathy and balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy,” Kidney International, vol. 81, no. 6, pp. 513–515, 2012.
- J. S. Li, “6 poisoning cases induced by xanthii fructus,” People's Military Surgeon, vol. 10, pp. 31–32, 1981.
- M. Turgut, C. C. Alhan, M. Gürgöze et al., “Carboxyatractyloside poisoning in humans,” Annals of Tropical Paediatrics, vol. 25, no. 2, pp. 125–134, 2005.
- W. Q. Su, “Siberian cocklour fruit-induced adverse drug reactions: literature analysis of 95 Cases,” Pharmacy Today, vol. 18, no. 5, pp. 44–46, 2008.
- E. S. Gurley, M. Rahman, M. J. Hossain et al., “Fatal outbreak from consuming xanthium strumarium seedlings during time of food scarcity in northeastern Bangladesh,” PloS one, vol. 5, no. 3, article e9756, 2010.
- J. Yu, J. Wang, R. Zhao, Z. Bao, and S. Cai, “Advances in studies of renal adverse reactions of leonurus heterophyllus,” China Journal of Chinese Materia Medica, vol. 35, no. 9, pp. 1213–1216, 2010.
- J. Wang, C. L. Mo, L. Que, G. Zhaori, and J. Yu, “Advances in studies on adverse effects of xanthii fructus,” Chinese Traditional and Herbal Drugs, vol. 42, no. 3, pp. 613–616, 2011.
- J. Yu, J. Xie, X. J. Mao et al., “Hepatoxicity of major constituents and extractions of radix polygoni multiflori and radix polygoni multiflori praeparata,” Journal of Ethnopharmacology, vol. 137, no. 3, pp. 1291–1299, 2011.
- Chinese Pharmacopeia Commission, Pharmacopoeia of the People’s Republic of China, vol. 1, China Medico-Pharmaceutical Science & Technology, Beijing, China, 2010.
- R. Duo, Y. Chen, Y. H. Liu, et al., “Influence of processing on contents of carboxyatractyloside and atractyloside in Xanthii Fructus,” Chinese Traditional Patent Medicine, vol. 35, no. 2, pp. 353–356, 2013.
- D. K. Obatomi, N. T. K. Thanh, S. Brant, and P. H. Bach, “The toxic mechanism and metabolic effects of atractyloside in precision-cut pig kidney and liver slices,” Archives of Toxicology, vol. 72, no. 8, pp. 524–530, 1998.
- M. J. Ryan, G. Johnson, J. Kirk, S. M. Fuerstenberg, R. A. Zager, and B. Torok-Storb, “HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney,” Kidney International, vol. 45, no. 1, pp. 48–57, 1994.
- S. Koul, S. Fu, and H. Koul, “Oxalate exposure promotes reinitiation of the DNA synthesis and apoptosis of HK-2 cells, a line of human renal epithelial cells,” Annals of the New York Academy of Sciences, vol. 1010, pp. 292–295, 2003.
- A. Ortiz, P. Justo, A. Sanz et al., “Tubular cell apoptosis and cidofovir-induced acute renal failure,” Antiviral Therapy, vol. 10, no. 1, pp. 185–190, 2005.
- R. A. Zager, “Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content,” American Journal of Kidney Diseases, vol. 36, no. 2, pp. 238–249, 2000.
- E. M. Scheers, B. Ekwall, and P. J. Dierickx, “In vitro long-term cytotoxicity testing of 27 MEIC chemicals on Hep G2 cells and comparison with acute human toxicity data,” Toxicology in Vitro, vol. 15, no. 2, pp. 153–161, 2001.